Novo Nordisk and Sangamo BioSciences Announce Agreement(09/12/2005) Novo Nordisk A/S and Sangamo BioSciences, Inc. announced an agreement that provides Novo Nordisk with access to Sangamo's proprietary zinc finger DNA-binding protein (ZFP) technology. Sangamo will provide its ZFP technology for Novo Nordisk to ...
Sangamo BioSciences Receives $2 Million Advanced Technology Program(05/05/2004) Third ATP Grant Awarded to Company Richmond, Calif. -- Sangamo BioSciences, Inc. announced that the company has been awarded an Advanced Technology Program (ATP) grant to conduct research on a novel application of Sangamo's zinc finger DNA binding protein transcription factor (ZFP ...
Top